Xponance Inc. grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 14.9% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 221,960 shares of the biopharmaceutical company's stock after buying an additional 28,744 shares during the quarter. Xponance Inc.'s holdings in Gilead Sciences were worth $24,871,000 at the end of the most recent reporting period.
Other hedge funds have also recently modified their holdings of the company. Brighton Jones LLC grew its stake in Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock worth $1,326,000 after purchasing an additional 2,450 shares in the last quarter. Proficio Capital Partners LLC bought a new position in Gilead Sciences in the fourth quarter worth approximately $339,000. Independent Advisor Alliance grew its stake in Gilead Sciences by 35.4% in the fourth quarter. Independent Advisor Alliance now owns 32,128 shares of the biopharmaceutical company's stock worth $2,968,000 after purchasing an additional 8,398 shares in the last quarter. Citizens Financial Group Inc. RI lifted its holdings in Gilead Sciences by 58.6% during the fourth quarter. Citizens Financial Group Inc. RI now owns 10,027 shares of the biopharmaceutical company's stock worth $926,000 after buying an additional 3,706 shares during the period. Finally, Avantax Planning Partners Inc. lifted its holdings in Gilead Sciences by 9.6% during the fourth quarter. Avantax Planning Partners Inc. now owns 3,659 shares of the biopharmaceutical company's stock worth $338,000 after buying an additional 322 shares during the period. Institutional investors own 83.67% of the company's stock.
Gilead Sciences Stock Performance
GILD traded down $4.90 during midday trading on Friday, hitting $109.64. 6,115,020 shares of the company were exchanged, compared to its average volume of 7,692,547. The company's 50 day simple moving average is $107.74 and its 200 day simple moving average is $104.61. The firm has a market capitalization of $136.38 billion, a price-to-earnings ratio of 23.08, a price-to-earnings-growth ratio of 0.74 and a beta of 0.29. The company has a current ratio of 1.37, a quick ratio of 1.23 and a debt-to-equity ratio of 1.16. Gilead Sciences, Inc. has a 1-year low of $69.91 and a 1-year high of $119.96.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The firm had revenue of $6.67 billion for the quarter, compared to analysts' expectations of $6.77 billion. During the same period last year, the firm earned ($1.32) EPS. The company's quarterly revenue was down .3% on a year-over-year basis. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.
Gilead Sciences Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.88%. The ex-dividend date was Friday, June 13th. Gilead Sciences's dividend payout ratio is presently 66.53%.
Insider Activity at Gilead Sciences
In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $110.17, for a total value of $275,425.00. Following the transaction, the chief financial officer directly owned 165,110 shares of the company's stock, valued at $18,190,168.70. This trade represents a 1.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction that occurred on Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the completion of the transaction, the insider directly owned 121,152 shares in the company, valued at $13,026,263.04. This trade represents a 18.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 58,500 shares of company stock valued at $6,340,745. 0.27% of the stock is owned by corporate insiders.
Analyst Ratings Changes
A number of analysts have weighed in on GILD shares. Morgan Stanley upped their target price on Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Cantor Fitzgerald started coverage on Gilead Sciences in a report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 target price for the company. JPMorgan Chase & Co. upped their target price on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a report on Thursday, March 27th. Oppenheimer lowered their target price on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, April 25th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Nine analysts have rated the stock with a hold rating, fourteen have given a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $111.38.
View Our Latest Research Report on Gilead Sciences
About Gilead Sciences
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Further Reading
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
